SG/CALL/ABBVIE/180/0.1/20.06.25 Stock

DE000SU2YL34

Real-time Boerse Frankfurt Warrants 11:53:15 2024-06-03 EDT
0.72 ^EUR	+2.86%

1 month	-27.08%
3 months	-59.54%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	08:31am	PR
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	05-31	MT
AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate	05-31	MT
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	05-31	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.72	+2.86%
24-05-31	0.7	+14.75%
24-05-30	0.61	+7.02%
24-05-29	0.57	+1.79%
24-05-28	0.56	-8.20%

Real-time Boerse Frankfurt Warrants

Last update June 03, 2024 at 11:53 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ABBVIE INC.
Issuer	Société Générale
WKN	SU2YL3
ISIN	DE000SU2YL34
Date issued	2023-11-29
Strike	180 $
Maturity	2025-06-20 (382 Days)
Parity	10 : 1
Emission price	0.41 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.04 €
Lowest since issue	0.35 €
Spread	0.03 €
Spread %	4.05%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company